Shilpa Medicare (SML) has entered into a binding agreement with NXI Therapeutics AG based out of Basel, Switzerland for development, supply of a New Chemical Entity (NCE). Under the terms of the strategic collaboration, SML will support both development – including first-in-human clinical studies – as well as long-term commercial supply with GMP manufacturing.